ANVISA News Today: Latest Updates From Brazil’s Health Agency

ANVISA News Today: What You Need to Know Right Now

If your work, health, or business connects to Brazil in any way, ANVISA is not just a government agency. It is the organization that decides what gets approved, what gets banned, what gets flagged as unsafe, and what rules the entire Brazilian health market must follow.

And yet, for most people outside Brazil and even many inside it, keeping up with ANVISA news is genuinely difficult. The agency publishes in Portuguese. Updates are spread across multiple channels. Regulatory decisions land without much warning.

This article fixes that. It explains what ANVISA is, what kinds of news it publishes, why those updates matter to you, and how to follow it effectively so you never miss something important.

Whether you work in pharma, healthcare, food, cosmetics, medical devices, or simply care about what is happening in Brazil’s health space, this is the guide you need.

Quick Answer

What is ANVISA and what kind of news does it publish today?

ANVISA is Brazil’s National Health Surveillance Agency. It regulates drugs, food, cosmetics, medical devices, tobacco, and health services. ANVISA publishes news on drug approvals and rejections, product safety alerts, import bans, regulatory consultations, and new health guidelines. Its decisions affect any company or individual doing health-related business in Brazil.

What Is ANVISA?
Why ANVISA News Matters to You
What Types of News Does ANVISA Publish?
ANVISA Drug and Medicine Approvals
ANVISA Safety Alerts and Product Recalls
ANVISA and Food Regulation News
ANVISA Cosmetics and Personal Care Regulation
ANVISA Medical Device Regulation
How ANVISA Makes Regulatory Decisions
How to Follow ANVISA News in English
ANVISA and International Businesses
ANVISA Public Consultations
How ANVISA Compares to Other Health Agencies
Common Mistakes When Tracking ANVISA News
Best Practices for Staying Updated
Frequently Asked Questions
Key Takeaways

What Is ANVISA?

ANVISA stands for Agência Nacional de Vigilância Sanitária. In English, that translates to the National Health Surveillance Agency of Brazil.

It was established in 1999 as an independent regulatory agency under Brazil’s Ministry of Health. ANVISA operates as a federal autarchy, which means it has administrative and financial independence. It does not simply follow orders from other ministries. It makes its own regulatory decisions based on science, law, and public health evidence.

ANVISA’s headquarters are in Brasília, and it has offices throughout Brazil. It employs thousands of technical staff including pharmacists, doctors, engineers, chemists, and legal and administrative professionals.

You can access ANVISA’s official information in English through its

[international portal at gov.br/anvisa/en and through its legacy English resource hub].

What Does ANVISA Regulate?

ANVISA’s scope covers a wide range of products and services. Understanding this scope helps you identify which ANVISA news is relevant to you.

Category	Examples
Medicines	Prescription drugs, generics, biologics, vaccines
Food	Processed food, additives, contaminants, packaging
Cosmetics	Skin care, hair care, makeup, personal hygiene
Medical devices	Implants, diagnostic equipment, surgical tools
Tobacco products	Cigarettes, cigars, electronic cigarettes
Sanitizing products	Disinfectants, antiseptics, sterilization products
Health services	Blood banks, hospitals, clinical labs
Ports and airports	Imported goods health control

ANVISA is Brazil’s equivalent of the FDA in the United States, the EMA in Europe, or the MHRA in the United Kingdom. But its regulatory framework is uniquely Brazilian and shaped by Brazil’s own legal system, which means you cannot assume that FDA or EMA approval automatically translates to ANVISA approval.

Why ANVISA News Matters to You

If you are reading this, there is a specific reason ANVISA is on your radar. Let’s be direct about why this agency’s news actually matters.

For Pharmaceutical and Biotech Companies

If you manufacture or distribute medicines and want to sell them in Brazil, ANVISA is the gatekeeper. It approves new drugs, certifies generic medicines, evaluates biosimilars, and reviews clinical trial protocols. A single ANVISA decision can open or close a billion-dollar market.

Companies operating in Brazil’s pharma space track ANVISA news daily. Missing a new requirement, a consultation deadline, or a changed guideline can cost months of regulatory delay.

For Medical Device Manufacturers

Brazil is one of the largest medical device markets in Latin America. ANVISA’s INMETRO and certification frameworks, its risk classification system, and its import authorization process are all things medical device companies must navigate. Regulatory news here is business-critical.

For Food and Cosmetics Businesses

Brazil has strict rules around food additives, labeling, contaminants, and cosmetic ingredient safety. ANVISA regularly updates its positive lists (what is allowed) and its prohibited substance lists. A change in either can require reformulation, relabeling, or market withdrawal.

For Healthcare Professionals

Doctors, pharmacists, and nurses in Brazil need to know about drug safety alerts, updated prescribing information, product recalls, and new guidelines on controlled substances. This information comes directly from ANVISA.

For Investors and Analysts

ANVISA decisions move markets. A major drug approval or a manufacturing suspension at a large pharmaceutical facility can shift stock prices and investment decisions. Following ANVISA news is part of responsible coverage of the Brazilian healthcare sector.

For General Readers

You may not work in pharma or healthcare. But if you use medicines, buy food, or consume cosmetics in Brazil, ANVISA’s actions affect what is safe and what is available to you.

What Types of News Does ANVISA Publish?

ANVISA is an active publisher. It does not limit itself to formal regulatory texts. Its communications span several categories that each serve a different purpose.

Regulatory Resolutions (RDC)

Resoluções da Diretoria Colegiada, known as RDCs, are ANVISA’s primary legal instruments. These are binding rules that establish requirements for products, processes, services, and facilities. When ANVISA publishes a new RDC, it changes the legal landscape for everyone in the affected sector.

Normative Instructions (IN)

Normative Instructions complement RDCs. They often provide technical detail and procedural guidance that helps industry comply with the broader regulatory framework set by an RDC.

Product Approvals and Registrations

ANVISA publishes notices when it grants, renews, denies, or cancels product registrations. These cover medicines, food products, cosmetics, medical devices, and more. This is some of the most closely watched ANVISA news in industry circles.

Safety Alerts and Risk Notices

When ANVISA identifies a risk, it acts publicly. Safety alerts cover product contamination, falsified medicines, undeclared ingredients in food or supplements, and defective medical devices. These are published quickly and often result in product suspensions or recalls.

Public Consultations (Consultas Públicas)

Before finalizing major regulations, ANVISA opens public consultations. These invite industry, researchers, patient groups, and the public to submit feedback. Following consultations gives you advance warning of regulatory changes and an opportunity to participate.

Prohibited and Suspended Products Lists

ANVISA maintains active lists of suspended, prohibited, and cancelled registrations. These are updated regularly and are essential for compliance monitoring.

International Cooperation News

ANVISA works with the Pan American Health Organization (PAHO), the World Health Organization (WHO), Mercosur regulatory partners, and bilateral partners including the United States FDA. News about these partnerships affects how Brazilian and international companies coordinate on regulatory submissions.

ANVISA Drug and Medicine Approvals

Drug approval is ANVISA’s most followed activity. Here is how the process works and what the news means when an approval is announced.

How Drug Registration Works in Brazil

Any medicine sold legally in Brazil must have an ANVISA registration number, known as the número de registro. This applies to prescription drugs, over-the-counter medicines, generics, similares (branded generics), biologics, and vaccines.

The approval process requires companies to submit a dossier demonstrating the drug’s safety, efficacy, and quality. ANVISA reviews the documentation and may request additional data before granting registration.

Priority Review for Innovative Medicines

ANVISA offers a priority review pathway for certain innovative medicines, particularly those addressing serious or rare diseases, tropical diseases, and pediatric conditions. Priority review shortens the review clock compared to standard pathways.

Generic Medicine Registration

Brazil has a well-developed generic medicines market. ANVISA regulates generics strictly. A generic must demonstrate bioequivalence to the reference drug. When ANVISA approves a new generic, it typically results in increased price competition and improved patient access.

Biosimilar Regulation

ANVISA has a dedicated pathway for biosimilars, which are near-identical versions of biological medicines. This area has grown significantly as major biologics face patent expiry. ANVISA’s biosimilar approvals are closely tracked by the pharmaceutical and investment communities.

What Happens When ANVISA Denies or Suspends a Medicine

A denial means ANVISA found insufficient evidence of safety, efficacy, or quality. A suspension means a product that was already approved has been flagged for a problem. Suspensions often happen when a safety signal emerges post-market or when a manufacturing facility fails inspection.

Both denials and suspensions are published and become part of ANVISA’s public record.

ANVISA Safety Alerts and Product Recalls

Safety alerts are some of the most time-sensitive ANVISA news. When ANVISA identifies a product that poses a risk to public health, it moves quickly.

What Triggers a Safety Alert

Contamination detected in a product on the market
Reports of adverse events linked to a specific product or batch
Discovery of falsified or counterfeit medicines
Undeclared allergens in food products
Unauthorized ingredients found in supplements or cosmetics
Defects in medical devices that create patient risk

What an ANVISA Safety Alert Includes

A typical safety alert will identify:

The product name and brand
The batch numbers or lot numbers affected
The nature of the risk
What consumers or health professionals should do
Whether the product is suspended or recalled
Contact information for the company

How Recalls Work in Brazil

ANVISA does not always order a recall directly. It may issue a suspension and require the manufacturer or distributor to execute the recall. ANVISA then monitors and verifies that the recall is completed properly.

Why Safety Alerts Matter Internationally

If a product flagged by ANVISA is also sold in other countries, there can be knock-on effects. Regulatory agencies in other countries may issue their own alerts based on ANVISA findings. International supply chains are interconnected, and a manufacturing problem in one country can affect products in another.

ANVISA and Food Regulation News

Food regulation is a major part of ANVISA’s work that often gets less attention than drug approvals but affects far more people daily.

What ANVISA Controls in Food

Permitted food additives and their maximum levels
Contaminant limits (pesticides, heavy metals, mycotoxins)
Nutritional labeling requirements
Health claims on food packaging
Food coloring and preservative rules
Packaging material safety
Genetically modified organism (GMO) labeling

Recent Direction in Brazilian Food Regulation

ANVISA has invested significant effort in updating Brazil’s food labeling framework to require clearer front-of-pack warnings about high sugar, salt, and saturated fat content. These changes affect how food companies design packaging for the Brazilian market.

For food manufacturers and importers, tracking ANVISA’s positive lists and contaminant limits is a compliance necessity. Limits can change. Ingredients that were permitted can become restricted. Missing a change can mean selling a non-compliant product.

Food Safety Investigations

When food contamination events occur, ANVISA leads the federal response alongside state health agencies. These investigations can result in product bans, company sanctions, and export restrictions.

ANVISA Cosmetics and Personal Care Regulation

Brazil is one of the world’s largest cosmetics markets. ANVISA’s cosmetics regulation directly shapes what can be sold there.

Cosmetics Classification in Brazil

ANVISA classifies cosmetics into two risk categories:

Category 1: Lower risk products like shampoos, soaps, and toothpaste. These require company notification rather than full registration.
Category 2: Higher risk products like hair dye, sunscreen, and antiperspirants. These require ANVISA registration before they can be sold.

This classification determines the compliance path and the depth of documentation required.

Prohibited and Restricted Ingredients

ANVISA maintains lists of prohibited substances in cosmetics and substances subject to restrictions. These lists are updated as new safety evidence emerges. Companies must check ingredient compliance against current lists, not outdated versions.

Cosmetics Recalls and Alerts

Like other product categories, cosmetics with quality problems or safety concerns can trigger ANVISA alerts. Common issues include microbial contamination, levels of restricted substances exceeding permitted limits, and undeclared allergens.

ANVISA Medical Device Regulation

Medical device regulation covers an enormous range of products. Everything from bandages to MRI machines falls under ANVISA’s jurisdiction.

Risk Classification

ANVISA classifies medical devices into four risk classes (Class I through Class IV), similar to the classification systems used by the FDA and EU. Higher-risk devices require more rigorous evaluation before they can be registered and sold.

Registration Requirements

Most medical devices require ANVISA registration before they can be marketed in Brazil. The registration dossier typically includes technical documentation, quality system certification, and evidence of compliance with applicable technical standards.

Good Manufacturing Practice (GMP) Compliance

ANVISA requires medical device manufacturers to comply with Good Manufacturing Practice standards. For foreign manufacturers, ANVISA may accept GMP certificates from recognized international bodies in some cases, but it also conducts its own inspections.

Importation and Customs Control

ANVISA controls the importation of health products at Brazilian ports and airports. Products entering Brazil without proper registration or documentation can be seized and destroyed.

How ANVISA Makes Regulatory Decisions

Understanding ANVISA’s decision-making process helps you understand its news and predict where regulation is heading.

The Board of Directors (Diretoria Colegiada)

ANVISA is governed by a collegiate board of directors. This board makes the agency’s most important regulatory decisions collectively. Board decisions are published in the Brazilian Official Gazette (Diário Oficial da União), which is the authoritative source for final regulatory actions.

Scientific and Technical Assessments

Before making decisions on drug or device approvals, ANVISA’s technical staff conduct detailed scientific reviews. These reviews assess clinical data, non-clinical data, manufacturing quality, and labeling.

Stakeholder Participation

Public consultations allow industry, civil society, researchers, and the general public to comment on proposed regulations before they are finalized. This participatory process is legally required for major regulatory changes in Brazil.

Transparency and Publication

ANVISA is legally required to publish its decisions. This makes ANVISA one of the more transparent health regulatory agencies in Latin America. Decisions, meeting minutes, approved product lists, and safety alerts are all publicly available.

How to Follow ANVISA News in English

This is where many people struggle. ANVISA publishes primarily in Portuguese. Its most detailed and timely information is in Portuguese. If you need to follow ANVISA news and do not speak Portuguese, you have several options.

ANVISA’s Official English Resources

ANVISA maintains an English-language section on its website. The [ANVISA international porta provides general information about the agency, its regulatory framework, and international cooperation activities. The

egacy English resource page] contains additional materials for international audiences.

These English resources are useful for understanding ANVISA’s structure and general regulatory approach. However, day-to-day news, alerts, and regulatory publications are primarily in Portuguese.

Translation Tools for ANVISA Content

For real-time translation of ANVISA publications, tools like Google Translate or DeepL can provide workable translations of Portuguese regulatory texts. The quality is imperfect for technical and legal language, but it is sufficient for a basic understanding of most news items.

For any business-critical decisions based on translated ANVISA content, always verify with a qualified professional who reads Portuguese, or a regulatory affairs specialist with Brazil experience.

Regulatory Intelligence Services

Several regulatory intelligence platforms track ANVISA publications and provide translated summaries for pharmaceutical, medical device, and food industry clients. These services often send alerts when relevant ANVISA news is published. For companies with significant Brazil exposure, these subscriptions are worth considering.

Legal and Regulatory Affairs Firms in Brazil

Law firms and regulatory consulting firms specializing in Brazilian health law actively monitor ANVISA and can provide timely analysis of important developments. If ANVISA news could affect your business operations, having local expertise on retainer is a practical investment.

Staying Ahead With Reliable News Sources

Keeping up with regulatory news is part of a broader challenge of information overload. If you find it hard to track news across multiple sources and sectors, reading about

[how to cut through the noise and find what matters in today’s news] can help you build a smarter system for staying informed.

ANVISA and International Businesses

For any company outside Brazil that wants to enter the Brazilian market with a health product, ANVISA is the primary regulatory authority you must engage with.

What International Companies Need to Know

Registration is required. You cannot legally sell medicines, medical devices, or many food and cosmetics products in Brazil without ANVISA registration.

A legal representative in Brazil is required. Foreign companies must designate a legal representative (responsável técnico) based in Brazil. This person takes legal responsibility for the product’s compliance in the Brazilian market.

Manufacturing inspections may be required. For medicines and certain medical devices, ANVISA may inspect your manufacturing site, even if it is outside Brazil. Alternatively, ANVISA may accept GMP certificates from recognized regulatory authorities in some situations.

Registration timelines vary. Depending on the product type and risk level, ANVISA registration can take anywhere from a few months to several years. Priority review pathways exist for certain products.

Fees apply. ANVISA charges fees (Taxas de Fiscalização de Vigilância Sanitária, or TFVS) for registration and renewal applications.

Regulatory Harmonization in Mercosur

Brazil is a member of Mercosur, the South American trade bloc. ANVISA participates in Mercosur’s regulatory harmonization efforts for pharmaceuticals and medical devices. This means some regulatory standards are being aligned across Argentina, Brazil, Paraguay, and Uruguay, which can simplify the registration process for products already approved in Mercosur partner countries in certain categories.

ANVISA and FDA Collaboration

ANVISA and the US Food and Drug Administration have maintained a cooperation agreement. This includes information sharing on drug manufacturing inspections and regulatory strategies. For US companies seeking Brazilian market entry, understanding how ANVISA and the FDA align and differ on specific requirements is important.

ANVISA Public Consultations

Public consultations are ANVISA’s formal mechanism for gathering input before finalizing new regulations. For industry professionals, these are one of the most important categories of ANVISA news to follow.

Why Public Consultations Matter

A public consultation gives you advance notice that a regulatory change is coming. It also gives you an opportunity to submit comments that can influence the final rule.

Missing a public consultation on a topic that affects your products means you get no input into a regulation you will later have to comply with.

How to Participate in an ANVISA Public Consultation

Monitor ANVISA’s official consultation page for open consultations relevant to your sector.
Review the proposed regulation and its supporting justification documents.
Prepare a written submission addressing the specific questions posed by ANVISA or raising your concerns.
Submit via ANVISA’s electronic participation system before the stated deadline.
Follow the consultation’s closure and the subsequent publication of the final regulation.

International companies can participate in ANVISA consultations. ANVISA does not restrict participation to Brazilian entities.

Post-Consultation Process

After a consultation closes, ANVISA reviews the submissions and may revise the proposed rule. It typically publishes a summary of how it responded to the main feedback before finalizing the regulation. This is called the Análise de Impacto Regulatório (Regulatory Impact Analysis).

How ANVISA Compares to Other Health Agencies

Understanding how ANVISA fits in the global regulatory landscape helps you work with it more effectively.

Feature	ANVISA (Brazil)	FDA (USA)	EMA (EU)	TGA (Australia)
Founded	1999	1906	1995	1989
Scope	Drugs, food, cosmetics, devices, tobacco	Drugs, food, devices, biologics	Drugs, devices, biologics	Drugs, devices, biologics
Legal framework	Brazilian federal law	US federal law	EU law	Australian law
Publication language	Portuguese	English	Multiple EU languages	English
International recognition	Growing	Highest globally	High	High
GMP inspection	Conducts own + accepts some bilateral	Conducts own globally	Conducts own + mutual recognition	Conducts own + mutual recognition
Public consultation	Yes, legally required	Yes	Yes	Yes

Key Difference: No Automatic Mutual Recognition

Unlike the situation between the FDA and EMA, where there is a Mutual Recognition Agreement on GMP inspections, ANVISA does not have equivalent mutual recognition agreements with most global agencies. This means foreign drug and device manufacturers often face a Brazil-specific regulatory pathway that cannot be shortcut by existing FDA or EMA approval alone.

Common Mistakes When Tracking ANVISA News

Relying Only on English Sources

Most ANVISA news is published in Portuguese first. Relying exclusively on English-language summaries means you are getting delayed and incomplete information. For business-critical monitoring, build access to Portuguese-language sources, even if that means using translation tools.

Confusing ANVISA Updates With State Health Agency Actions

Brazil has state-level health surveillance agencies (Vigilâncias Sanitárias Estaduais) that also issue alerts and take enforcement actions. These are separate from ANVISA. A state agency action may affect only one state, while an ANVISA action is federal and covers all of Brazil.

Ignoring Consultation Notices

Many businesses only read final regulations. By then, it is too late to influence the outcome. Tracking public consultations is essential for staying ahead of regulatory change.

Assuming Approval in One Country Means Approval in Brazil

This is a very common mistake for international companies. FDA approval does not mean ANVISA approval. EMA approval does not mean ANVISA approval. Each market requires its own registration process.

Not Monitoring Prohibited Lists Regularly

ANVISA’s lists of prohibited and suspended substances and products are dynamic. They change. A company that checked a list once and never checked again may be selling a product that has since been suspended.

Using the Wrong Portal

ANVISA has both a legacy portal (antigo.anvisa.gov.br) and a current main portal (gov.br/anvisa). Some content exists only on one or the other. Use both, depending on what you are looking for.

Best Practices for Staying Updated on ANVISA News

Set Up Monitoring for Your Product Categories

Do not try to follow all ANVISA news. Focus on the categories that affect your work. If you are in pharmaceuticals, follow drug approvals, safety alerts, and clinical trial regulations. If you are in food, follow labeling rules, contaminant limits, and food additive consultations.

Use ANVISA’s Official Channels Directly

The most reliable source of ANVISA news is ANVISA itself. Bookmark the official portal and check it regularly. Do not rely exclusively on third-party summaries, which can lag, simplify, or mischaracterize official publications.

Follow the Diário Oficial da União

The Brazilian Official Gazette is the authoritative publication for all final regulatory decisions. Major ANVISA actions are published here first. You can subscribe to receive daily editions, which you can then search for ANVISA-related content.

Build a Brazil-Specific Regulatory Intelligence Workflow

For businesses with significant Brazil exposure, a structured workflow matters more than occasional checking. Assign responsibility, use monitoring tools, build a calendar of consultation deadlines, and document your regulatory tracking for compliance purposes.

Stay Connected With AI-Powered News Tools

AI-driven news aggregation tools are increasingly capable of filtering regulatory news by agency, country, and product category. If you struggle to stay current across multiple regulatory environments, reading about

[how AI is changing the way we consume news today] can help you find better tools for the job.

Frequently Asked Questions

What is ANVISA?

ANVISA is Brazil’s National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária). It is an independent federal regulatory authority responsible for overseeing medicines, food, cosmetics, medical devices, tobacco, and health services in Brazil. It was established in 1999.

Does ANVISA publish news in English?

ANVISA publishes some general information and international cooperation content in English through its official international portal. However, the majority of its regulatory publications, safety alerts, and approvals are published in Portuguese. Translation tools and regulatory intelligence services can help non-Portuguese speakers follow ANVISA news.

How often does ANVISA publish new regulatory decisions?

ANVISA publishes regulatory decisions on an ongoing basis throughout the year. Product registrations, safety alerts, normative texts, and consultation notices can appear on any given day. There is no fixed schedule for individual publications.

Is ANVISA approval the same as FDA approval?

No. ANVISA and the FDA are separate regulatory authorities in separate countries with separate legal frameworks. A product approved by the FDA is not automatically approved by ANVISA. Companies that want to sell health products in Brazil must go through ANVISA’s registration process separately.

How do I submit a complaint to ANVISA?

ANVISA accepts complaints from consumers and industry through its Disque Saúde (Health Hotline) system and its electronic complaint platform. Complaints can cover product quality problems, adverse events, suspected counterfeit products, and regulatory violations.

What is an ANVISA RDC?

RDC stands for Resolução da Diretoria Colegiada, which translates to Collegiate Board Resolution. RDCs are ANVISA’s primary binding regulatory instruments. They establish requirements that companies and products must meet. When a new RDC is published, it typically creates new compliance obligations for the affected sector.

How long does ANVISA drug registration take?

The timeline varies depending on the type of medicine and the review pathway. Standard registration can take from 12 months to several years. Priority review pathways for certain innovative medicines can be shorter. Generic medicines follow separate pathways with different timelines.

Can foreign companies register products directly with ANVISA?

Foreign companies must designate a legal representative based in Brazil to register health products with ANVISA. This representative is legally accountable for the product’s compliance in the Brazilian market. Some product categories also require local manufacturing partnerships or importation authorization.

What should I do if ANVISA issues a safety alert on a product I use?

Follow the specific instructions in the alert. If the product is recalled, stop using it and follow the instructions for returning or disposing of it safely. Contact the product’s manufacturer or distributor for specific guidance. For medicines, consult your healthcare provider about alternative treatment options.

How is ANVISA funded?

ANVISA is funded through a combination of government budget allocation and regulatory fees charged to industry for registration, renewal, and licensing services. This mixed funding model is intended to support the agency’s operational independence.

Key Takeaways

Here is the short version of everything this article covers.

ANVISA is Brazil’s top health regulatory agency. It oversees medicines, food, cosmetics, medical devices, tobacco, and health services.
ANVISA publishes several types of news. These include product approvals, safety alerts, new regulations (RDCs), public consultations, and enforcement actions.
ANVISA’s news matters to many audiences. Pharmaceutical companies, food businesses, cosmetics manufacturers, medical device makers, healthcare professionals, and investors all need to follow it.
Most ANVISA content is in Portuguese. English resources exist but are limited. Translation tools and regulatory intelligence services fill the gap.
ANVISA approval is separate from FDA or EMA approval. International companies must complete Brazil-specific registration, regardless of approvals in other markets.
Public consultations are the best advance warning of regulatory change. Following them gives you input and preparation time before new rules take effect.
Safety alerts require prompt action. When ANVISA flags a product, distributors, retailers, and healthcare providers need to respond quickly.
A local legal representative is required for product registration. Foreign companies cannot register directly without a Brazilian-based responsável técnico.
ANVISA is one of the most transparent regulatory agencies in Latin America. Its publications are public and searchable, which makes monitoring feasible for anyone willing to build the right workflow.

Following ANVISA news consistently is not complicated. It just requires knowing where to look, what to look for, and how to act on what you find. Start with the official English portal, build your monitoring system around the product categories relevant to you, and use translation tools and local expertise where the language gap becomes a problem.